Cost-Utility Analysis of Denosumab Versus Alendronate For Postmenopausal Osteoporosis In South Korea
Sep 1, 2018, 00:00
10.1016/j.jval.2018.07.613
https://www.valueinhealthjournal.com/article/S1098-3015(18)32970-X/fulltext
Title :
Cost-Utility Analysis of Denosumab Versus Alendronate For Postmenopausal Osteoporosis In South Korea
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)32970-X&doi=10.1016/j.jval.2018.07.613
First page :
Section Title :
Open access? :
No
Section Order :
534